ALK and lung adenocarcinoma: Mutations in genes such as the Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), ROS1 Proto-Oncogene Tyrosine Kinase Receptor (ROS1), and Serine/Threonine-Protein Kinase BRAF (BRAF) are therapeutic targets in lung adenocarcinoma, and novel mutations may be introduced as targeted therapies [5].